The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse The asthma control rate achieved by budesonide/formoterol in clinical practice in China
- collapse Oxis 9mcg Turbuhaler Clinical Experience Investigation
- collapse Perception of symptom variability in Chinese COPD patients
- collapse Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms
- collapse Symbicort Turbulaler 30/60 Special Clinical Experince Investigation for long-term use for COPD patients
- collapse A Phase 2, Open-Label Extension Study to Evaluate Long-Term Safety of MEDI-546 in Adults with Systemic Lupus Erythematosus
- collapse A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma
- collapse An Observational Study to Assess Respiratory Syncytial Virus (RSV)-Associated Illness in Adults with Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)
- collapse A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MEDI-557 in Healthy Adults Intranasally Challenged with Respiratory Syncytial Virus (RSV)
- collapse A Phase 2 Exploratory Study of Mavrilimumab versus Anti-Tumor Necrosis Factor in Subjects with Rheumatoid Arthritis
